EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy

Francesco Saccà iD, Emmanuelle Salort-Campana, Saiju Jacob, Elena Cortés-Vicente iD, Christiane Schneider-Gold iD

European Journal of Neurology · 2024-06 · 31 (6)

DOI: 10.1111/ene.16180 ↗

At a glance

Übersichtsarbeit in European Journal of Neurology, published online on 2023-12-20. Written by Francesco Saccà and 4 co-authors. Institution: Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy. Major MEDLINE topics: Myasthenia Gravis. Cited 52 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and purpose Generalized myasthenia gravis (gMG) continues to present significant challenges for clinical management due to an unpredictable disease course, frequent disease fluctuations, and varying response to therapy. The recent availability of new pharmacologic therapies presents a valuable opportunity to reevaluate how this disease is classified, assessed, and managed and identify new ways to improve the clinical care of patients with gMG.

Methods

Narrative review was made of publications identified via searches of PubMed and selected congresses (January 2000–September 2022).

Results

New consensus definitions are required to ensure consistency, to better characterize patients, and to identify patients who will benefit from specific drugs and earlier use of these agents. There is a need for more frequent, standardized patient assessment to identify the cause of motor function deficits, provide a clearer picture of the disease burden and its impact on daily living and quality of life (QoL), and better support treatment decision‐making. Novel approaches that target different components of the immune system will play a role in more precise treatment of patients with gMG, alongside the development of new algorithms to guide individualized patient management. Conclusions gMG has a physical, mental, and social impact, resulting in a considerable burden of disease and substantially decreased QoL, despite standard treatments. The availability of novel, targeted treatments that influence key pathological mediators of gMG, together with new biomarkers, offers the potential to optimize patient management and ultimately enables a greater number of patients to achieve minimal manifestation status and a reduced burden of disease.

Subjects

MeSH terms (MEDLINE)

Myasthenia GravisHumansCost of IllnessQuality of Life

Author keywords

classificationdisease burdengeneralized myasthenia gravispathophysiologytargeted therapy

Authors and institutions

  • Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy.
  • Reference Center of Neuromuscular Disorders and ALS, Timone University Hospital, Assistance Publique-Hopitaux de Marseille, Marseille, France.
  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau and Biomedical Research Institute Sant Pau, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Neurology, St. Josef Hospital of Ruhr-University Bochum, Bochum, Germany.

ORCID profiles: Francesco Saccà, Elena Cortés-Vicente, Christiane Schneider-Gold

Cite

APA

Saccà, F., Salort-Campana, E., Jacob, S., Cortés-Vicente, E., & Schneider-Gold, C. (2024). Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. European Journal of Neurology, 31(6). https://doi.org/10.1111/ene.16180

Vancouver

Saccà F, Salort-Campana E, Jacob S, Cortés-Vicente E, Schneider-Gold C. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. European Journal of Neurology. 2024;31(6). doi:10.1111/ene.16180

BibTeX
@article{Sacc2024,
  author = {Saccà, Francesco and Salort-Campana, Emmanuelle and Jacob, Saiju and Cortés-Vicente, Elena and Schneider-Gold, Christiane},
  title = {Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {6},
  doi = {10.1111/ene.16180}
}
Start for free →